Pharmaco - Today Stories

Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature and the benefits of complete testing Clinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) tests RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 1, 2023 /PRNewswire/ -- More than 35 million adults in the U.S. have chronic kidney disease (CKD). However, as many as 90% of them are unaware of their condition. This is despite clinical guidelines, which show that using two tests can help detect it. That's why Boehringer Ingelheim and Eli L…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, now presents itself with a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners, and employees. The evolved brand includes several striking changes including the introduction of a standout color palette and Boehringer Ingelheim’s first-ever brand claim “Life forward”. The claim builds on the foundation of the company purpose of 'transforming lives for generations’ and emphasizes how the company behaves in response to present-day and future challenges and the impact it intends to make. As a key player in the industry, Boehringer Ingelheim pioneers breakthrough treatments in some of the most devastating disease areas. With the rise of non-communicable a…

– The New Report Also Recognized Gilead As the Number One Funder of Organizations Focused on Achieving Health Equity for Key Populations, Including U.S. BIPOC Communities, Transgender Communities and Gay Men – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today was recognized as the number one philanthropic funder of HIV-related programs for the second year in a row, in a new report released by Funders Concerned About AIDS (FCAA). FCAA’s annual Philanthropic Support to Address HIV and AIDS report is widely regarded as the most comprehensive study of its kind, and analyzed data from more than 5,000 grants, disbursed by 187 funders and awarded to 2,800 grantee organizations. The 2023 report analyzed 2021 funding data – the most recent yearly data available – a…

Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitis Roche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1 Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment of US$ 150 million Basel, 23 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, I…

Roche will gain the rights to develop, manufacture and commercialise RVT-3101 in the US and Japan for the treatment of inflammatory bowel disease and potentially multiple other diseases RVT-3101 is a Phase 3-ready antibody with first-in-class and best-in-disease potential, a novel mode of action and strong Phase 2b data in ulcerative colitis Roche will also obtain an option to enter into a global collaboration with Pfizer on a next-generation p40/TL1A directed bispecific antibody, currently in Phase 1 Under the terms of the agreement, Roche will pay a purchase price of US$ 7.1 billion upfront and a near-term milestone payment of US$ 150 million Basel, 23 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire Telavant Holdings, I…

Ongoing Support for Breast Cancer Patients Through Initiatives Focused on Education and Elevating Patient Voices IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Yesterday, on Breast Reconstruction Awareness Day (National BRA Day), Allergan Aesthetics, an AbbVie company (NYSE: ABBV), launched Reblossom, a coffee table book featuring a collection of patient stories and photographs that celebrates the resilience of breast cancer survivors and thrivers. The Reblossom book was created through the support of Allergan Aesthetics by photographer Erez Sabag in collaboration with Board-Certified Plastic Surgeon, Dr. Jonathan Bank. Reblossom explores the stories of 12 women and their unique journeys with breast cancer and breast reconstruction. All proceeds from the purchase of the Reblossom book benef…

65 physicians comprise Cohort III, bringing the total to 179 participants in the program’s third year PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb Foundation (BMS Foundation), together with Virginia Commonwealth University (VCU), the American Association for Cancer Research (AACR), Gilead Sciences, Inc., and Amgen today announced that an additional 65 physicians have been selected to receive the Robert A. Winn Diversity in Clinical Trials Career Development Award (Winn CDA). The broader Robert A. Winn Diversity in Clinical Trials Award Program (Winn Award Program) aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity. The third cohort of physician…

Enhances Thermo Fisher’s Capabilities in the High-Growth Proteomics Market with the Addition of Highly Differentiated Solutions Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportunities WALTHAM, Mass. & UPPSALA, Sweden--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions, today announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash. This represents a premium of approx…

Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments. “Hypertension is a leading risk factor for cardiovascular events, heart failure,…

Test is available through physicians for use with patients being evaluated for possible Alzheimer's disease or other causes of cognitive impairment Labcorp is the first company to deliver a blood-based Amyloid-Tau-Neurodegeneration (ATN) Profile, which uses a trio of blood biomarkers to detect the hallmarks of Alzheimer's disease BURLINGTON, N.C., Oct. 11, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and national availability of its ATN Profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer's disease – amyloid plaques, tau tangles and neurodegeneration (ATN) – which can help accelerate the path to diagno…

2024 marks the 38th year of the PM Society Awards which celebrate creativity, impact, and innovation in pharma and healthcare communications. We are delighted that Twist Health will be our headline sponsor for the second year running. We are pleased to announce that the awards are now open for entry! This year’s categories are: Product Promotion (Single Piece) Product Brand Campaign Best Promotional Campaign for a Company or Initiative Charity or Patient Organisation including Pro-Bono Internal Communications Best Creative Medical Education Programme or Campaign Meetings, Events and Exhibitions Disease Awareness: Public/Patients (including Film and Animation) Disease Awareness: HCPs (including Film and Animation) Patient Support Agency Self Promotion and Internal Communication Best Use of…

Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati’s Promising Pipeline Includes a Potent Selective PRMT5/MTA Inhibitor, MRTX1719, a Potential First-in-Class and Best-in-Class Asset; and Early Clinical Pipeline Feature…

Increased capability to produce medicines for challenging diseases including cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders. Thermo Fisher made a significant investment since 2021 to add 58,000 square feet of biologics manufacturing space. The addition was facilitated by state and local tax incentives, including a 10-year new project abatement beginning in 2024. The company employs more than 1,000 people in the state of Missouri and more than 900 work at the site. “We’re providing our customers with greater flexibility to scale manufacturing and better serve patient…

Labcorp to acquire Baystate Health's outreach laboratory business and select operating assets Collaboration to improve access and enhance affordable, high-quality healthcare services for underserved communities across Massachusetts BURLINGTON, N.C., Oct. 4, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing. In addition, Labcorp will…

Girls Inc. alumnae in New York, San Antonio and Central Alabama will participate in a virtual panel titled 'Equipping the New Generation of STEM Leaders' with leading women physicians sharing their career journeys including growth moments and challenges A social media campaign shares authentic stories and aspirations of girls entering the workforce IRVINE, Calif., Oct. 3, 2023 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women's trajectories through college and career entry. The Allergan Aesthetics effort will focus specifically on leadership paths in STEM (science, technology, engineering, and ma…

CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece AbbVie will discuss the data with health authorities in the near future to further understand the potential of venetoclax as a biomarker-driven therapy in multiple myeloma NORTH CHICAGO, Ill., Sept. 29, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from its Phase 3 CANOVA study evaluating the safety and efficacy of venetoclax (VENCLEXTA®/ VENCLYXTO®) plus dexamethasone (VenDex) for patients with t(11;14)-positive relapsed or refractory (R/R) multiple myeloma who have received two or more prior treatments. Data did not demonstrate…

94% of Advanced Practice Providers (APPs) believe more educational resources about the rare blood cancer multiple myeloma could help improve the patient experience HORSHAM, Pa., September 26, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with the Advanced Practitioner Society for Hematology and Oncology (APSHO), today announced the launch of Make It HAPPen™, a multi-year effort designed to recognize and support Advanced Practice Providers (APPs) in the life-changing care they provide to people living with multiple myeloma. The campaign launched in response to a recent national survey, which showed that, among people who are living with multiple myeloma, most (93%) viewed APPs as essential to their care, and more than half (61%) felt they could ask t…

TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company’s gene therapy and auditory programs. The acquisition of Decibel builds on prior collaboration between the companies and includes three ongoing gene therapy programs targeting different forms of congenital, monogenic hearing loss. The most advanced clinical-stage candidate is DB-OTO, which is currently being studied in the global Phase 1/2 CHORDTM clinical trial, and is an investigational cell-selective, adeno-associated virus (AAV) gene therapy designed to provide durable, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of…

Breakthrough Expands its International Footprint, Entering the Burgeoning Amsterdam Life Science Community in Partnership with the Amsterdam University Medical Center Anticipated to be One of the World's Most Advanced and Sustainable Laboratory Environments, Kavel F by Breakthrough Aims to Achieve Carbon Negative Operations and a BREEAM Outstanding Rating AMSTERDAM, Sept. 21, 2023 /PRNewswire/ -- Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions. Neogene Therapeutics (Neogene), a wholly owned subsidiary of global biopharmaceutical c…

Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer Inc. (Pfizer). These new resources build on the combined capabilities of Alexion and AstraZeneca in genomic medicine, with the objective to develop new genetic therapies with improved safety and efficacy profiles. Additionally, several of the Pfizer employees associated with the portfolio will join Alexion as employees. Financial considerations Alexion has purchased and licenced the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total consideration of up to $1bn, plus tiered royalties on sales. Notes Alexion Alexion, AstraZeneca Rare Disease, is the group within AstraZ…